Short Interest in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Drops By 34.2%

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the recipient of a large drop in short interest during the month of July. As of July 15th, there was short interest totaling 29,440 shares, a drop of 34.2% from the June 30th total of 44,712 shares. Based on an average daily volume of 59,063 shares, the short-interest ratio is currently 0.5 days. Currently, 0.1% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Barinthus Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $4.00.

Institutional Trading of Barinthus Biotherapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Rangeley Capital LLC increased its stake in Barinthus Biotherapeutics by 88.8% in the first quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock valued at $91,000 after purchasing an additional 75,024 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Barinthus Biotherapeutics by 115.8% during the fourth quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock worth $100,000 after buying an additional 76,800 shares during the period. Finally, Baird Financial Group Inc. boosted its stake in shares of Barinthus Biotherapeutics by 108.2% during the second quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock worth $179,000 after buying an additional 100,000 shares during the period. 25.20% of the stock is owned by hedge funds and other institutional investors.

Barinthus Biotherapeutics Price Performance

Shares of NASDAQ BRNS traded up $0.03 during midday trading on Friday, hitting $0.58. 26,383 shares of the company’s stock were exchanged, compared to its average volume of 42,098. The firm’s fifty day simple moving average is $0.66 and its 200-day simple moving average is $0.65. The company has a market cap of $23.81 million, a PE ratio of -0.45 and a beta of -0.41. Barinthus Biotherapeutics has a twelve month low of $0.51 and a twelve month high of $1.83.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.14.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.